Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials

Código QR

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials

Kazuto Oya, Taro Kishi, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan Objective: We conducted a systematic review and meta-analysis of the efficacy of aripiprazole once monthly (AOM) for schizophrenia.Methods: Randomized controlled trials...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Oya K, Kishi T, Iwata N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/6348906a4da246659d1fb56fd6376c4e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Okuyama Y, et al.
Publicado: (2016)

Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials
por: Kishi T, et al.
Publicado: (2015)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang SM, et al.
Publicado: (2014)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
por: De Hert M, et al.
Publicado: (2015)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi T, et al.
Publicado: (2016)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
por: Madera JJ, et al.
Publicado: (2019)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Delia Bishara
Publicado: (2010)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa JK, et al.
Publicado: (2012)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi T, et al.
Publicado: (2017)

Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis
por: David D. Kim, et al.
Publicado: (2021)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi T, et al.
Publicado: (2018)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury AC, et al.
Publicado: (2021)

Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials
por: Luan SX, et al.
Publicado: (2018)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
por: Kishi T, et al.
Publicado: (2014)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si T, et al.
Publicado: (2019)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
por: Peters-Strickland T, et al.
Publicado: (2019)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb N, et al.
Publicado: (2012)

Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
por: Torres-Llenza V, et al.
Publicado: (2018)

Aripiprazole-associated tic in a schizophrenia patient
por: Guo X, et al.
Publicado: (2015)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

Efficacy and tolerability of pramipexole for the treatment of primary restless leg syndrome: a meta-analysis of randomized placebo-controlled trials
por: Zhang W, et al.
Publicado: (2013)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
por: Li HF, et al.
Publicado: (2015)

Comparative efficacy, acceptability, and tolerability of dexmethylphenidate versus placebo in child and adolescent ADHD: a meta-analysis of randomized controlled trials
por: Maneeton N, et al.
Publicado: (2015)

Melatonin receptor agonists—ramelteon and melatonin—for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi T, et al.
Publicado: (2019)

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi T, et al.
Publicado: (2018)

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole
por: Izchak Kohen, et al.
Publicado: (2010)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
por: Cai SL, et al.
Publicado: (2015)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews M, et al.
Publicado: (2018)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley R, et al.
Publicado: (2017)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
por: Wani RA, et al.
Publicado: (2015)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
por: O'Donnell A, et al.
Publicado: (2021)

Aripiprazole for late-life schizophrenia
por: Jeffrey Rado, et al.
Publicado: (2010)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi T, et al.
Publicado: (2014)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
por: Wani RA, et al.
Publicado: (2015)

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
por: Madera J, et al.
Publicado: (2019)

Memantine for the treatment of frontotemporal dementia: a meta-analysis
por: Kishi T, et al.
Publicado: (2015)

Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation
por: Christoph U. Correll, et al.
Publicado: (2020)

A randomized controlled trial of a mindfulness-based intervention program for people with schizophrenia: 6-month follow-up
por: Wang LQ, et al.
Publicado: (2016)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao Y, et al.
Publicado: (2013)

Efficacy and safety of oxcarbazepine in the treatment of children with epilepsy: a meta-analysis of randomized controlled trials
por: Geng H, et al.
Publicado: (2017)